Promedior Presents Encouraging Results From Clinical Study of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis
5/23/2013
More...
|
Virobay Inc. Initiates a Phase 1 Trial of VBY-036, a Compound Intended for the Treatment of Neuropathic Pain
5/23/2013
More...
|
Spring Bank Pharmaceuticals, Inc. Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
5/23/2013
More...
|
First Patient Dosed in the Phase I/II Study of Umecrine Mood’s Candidate Drug for Premenstrual Dysphoric Disorder
5/23/2013
More...
|
Protalex, Inc. (PRTX) Reports Positive Interim Review of Phase 1b Trial of PRTX-100 in Rheumatoid Arthritis by Independent Data Safety Monitoring Committee
5/22/2013
More...
|
Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer
5/22/2013
More...
|
ChemoCentryx, Inc. (CCXI) Announces Phase I Data With CCX507, Company's New Generation Orally Administered CCR9 Inhibitor
5/21/2013
More...
|
Medivir AB (MVIRb.F) Release: Positive Results From a Phase Ia Study With MIV-711 for the Treatment of Skeletal Disorders
5/21/2013
More...
|
NeuroSigma, Inc. Release: Positive Results Reported for Phase I Clinical Trial at University of California, Los Angeles (UCLA) for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)
5/21/2013
More...
|
CytRx Corporation (CYTR) Announces Initial Results From Pharmacokinetics Clinical Trial With Aldoxorubicin in Solid Tumors
5/21/2013
More...
|
Addex Therapeutics (ADXN.SW) Validates Potential Efficacy Biomarker for Phase 1 Trial of Its GABA-B Positive Allosteric Modulator, ADX71441
5/21/2013
More...
|
Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
5/20/2013
More...
|
Immunicum AB Release: Promising Data for Cancer Vaccine INTUVAX™ in the Treatment of Kidney Cancer
5/20/2013
More...
|
Sorrento Therapeutics, Inc. Announces Its Approach to Developing Human Antibody Therapeutics Against MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases
5/20/2013
More...
|
Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
5/20/2013
More...
|
R-Tech Ueno: Start of the Patient Enrollment of a Phase I/II Clinical Study of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) in U.S. for the Treatment of Severe Dry Eye
5/20/2013
More...
|
Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-Resistant Epilepsy
5/17/2013
More...
|
A*STAR and Cytos Biotechnology AG Bring Singapore's First Influenza Vaccine to Clinical Testing
5/17/2013
More...
|
AREVA Med LLC Med Presents Pharmacokinetics Data From Phase 1 Clinical Trial at SNMMI
5/17/2013
More...
|
Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
5/17/2013
More...
|
ZIOPHARM Oncology, Inc. (ZIOP.OB) Announces Presentation of Promising Nonclinical and Phase I Study Results of Ad-RTS-IL-12 in Advanced Melanoma at ASGCT 16th Annual Meeting
5/16/2013
More...
|
TG Therapeutics, Inc. (MHA) Announces Presentation of Phase 1 Data for Single-Agent Ublituximab (TG-1101) at the American Society of Clinical Oncology Meeting on June 2, 2013
5/16/2013
More...
|
Promedior to Present Clinical Data on Lead Drug Candidate, PRM-151, in Patients With IPF at the American Thoracic Society 2013 Annual Meeting
5/16/2013
More...
|
Successful Phase One Demonstrates Tumor Response With Increased Overall Survival for Lead VBL Therapeutics Compound in Cancer
5/16/2013
More...
|
Jennerex, Inc. Announces Science Translational Medicine Publication Highlighting Pexa-Vec's Ability to Induce Functional Anti-Cancer Immunity in Patients With Diverse Tumor Types
5/16/2013
More...
|
Ultragenyx Pharmaceuticals Advances Clinical Development of UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
5/15/2013
More...
|
Soligenix (SNGX.OB) Initiates Phase 1 Clinical Study With SGX203 for the Treatment of Pediatric Crohn's Disease
5/15/2013
More...
|
OncoMed Pharmaceuticals, Inc. Initiates Phase 1b/2 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 (Anti-Notch2/3) in Small Cell Lung Cancer (SCLC) and Amends Phase1b/2 Pancreatic Cancer Trial
5/15/2013
More...
|
Mirna Therapeutics, Inc. is First to Advance MicroRNA into the Clinic for Cancer
5/13/2013
More...
|
Marina Biotech, Inc. Announces That Licensee Mirna Therapeutics, Inc. Reported Initiation of a Phase 1 Clinical Trial of Anticancer Drug MRX34
5/13/2013
More...
|
Theravalues Release: A Clinical Study Shows the Theracurmin®'s Safety and Potential Role in Improving Quality of Life (QOL) of Pancreatic Cancer Patients
5/10/2013
More...
|
AtheroNova Inc. (AHRO.OB) Announces Approval for Phase 1 by the Russian Ministry of Healthcare With Commencement of Human Trials Imminent
5/9/2013
More...
|
Patrys Limited (PAB.AX) Release: PAT-SM6 Kills Human Multiple Myeloma Cells
5/8/2013
More...
|
Imperial Innovations' Cell Medica Treats First Paediatricpatient in Clinical Trial of Cytovir ADV
5/8/2013
More...
|
FOLFIRINOX Followed by Chemoradiation Shows Substantial Activity in Locally Advanced Pancreatic Cancer
5/8/2013
More...
|
New Data Presented Demonstrates Ovulatory Effect of Teva Women's Health, Inc. (TEVA)’s Investigational 28-Day Oral Contraceptive
5/8/2013
More...
|
Xcovery Vision Presents VEGFR/PDGFR Oral Inhibitor X-82 Preliminary Data for Wet AMD at Association for Research in Vision & Ophthalmology
5/8/2013
More...
|
Eleven Biotherapeutics Presents Data on EBI-005, a Novel IL-1 Inhibitor Protein Therapeutic for Topical Treatment of Dry Eye Disease
5/8/2013
More...
|
Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) (SRPT) Initiates Dosing in Phase I Multiple Ascending Dose Study of Drug for Treatment of Marburg Virus
5/7/2013
More...
|
Aileron Therapeutics Successfully Completes First-Ever Stapled Peptide Clinical Trial
5/7/2013
More...
|
Etubics Platform Generates Solid Immune Response in Colorectal Cancer Patients
5/7/2013
More...
|
Bristol-Myers Squibb Company (BMY), AstraZeneca PLC (AZN) Release: Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients With Lipodystrophy During a 12-Month Period
5/6/2013
More...
|
Senesco Technologies, Inc. (SNT) Announces Start of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma
5/6/2013
More...
|
Trevi Therapeuitcs Commences Clinical Study of Nalbuphine ER
5/6/2013
More...
|
La Jolla Pharmaceutical Company (LJPC) Announces Completion of Phase 1 Portion of GCS-100 Clinical Trial in Chronic Kidney Disease
5/6/2013
More...
|
Etubics Platform Generates Solid Immune Response in Colorectal Cancer Patients
5/6/2013
More...
|
Etubics Platform Generates Solid Immune Response in Colorectal Cancer Patients
5/6/2013
More...
|
Sunshine Biopharma, Inc. Narrows Kilogram Manufacturing Options for Adva-27a Breast Cancer Drug Candidate to Three Suppliers
5/1/2013
More...
|
Portola Pharmaceuticals, Inc. Announces Oral Presentation of Data on PRT4445, Factor Xa Inhibitor Antidote, at ATVB Scientific Sessions
4/30/2013
More...
|
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Completion of Patient Enrollment in Breast Cancer Clinical Trial for Bavituximab
4/30/2013
More...
|
Journal of Clinical Endocrinology & Metabolism Publishes Positive Versartis, Inc. Phase I Data
4/30/2013
More...
|
Transition Therapeutics Inc. (TTH.TO) Study on Type 2 Diabetes Better Than Expected
4/30/2013
More...
|
NeuralStem Inc. ALS Trial Data Presented at the American Association of Neurological Surgeons Annual Meeting
4/29/2013
More...
|
Durata Therapeutics, Inc. (DRTX) Release: Phase I Data Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of Dalbavancin Presented at the 23rd Annual ECCMID Meeting
4/29/2013
More...
|
Third Party Research Study Demonstrates Pluristem Therapeutics (PSTI)'s PLX-PAD Cells' Safety in Human Lung Models of Pulmonary Hypertension
4/29/2013
More...
|
Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
4/25/2013
More...
|
Lixte Biotechnology Announces Initiation of a Phase I Trial of Its Lead Anti-Cancer Compound, LB-100
4/25/2013
More...
|
Patrys Limited (PAB.AX) Progresses Multiple Myeloma Clinical Trial to Third Patient Group
4/24/2013
More...
|
Baxter International, Inc. (BAX) Presents Phase I/II Data Evaluating Lyme Disease Vaccine at NFID Annual Conference on Vaccine Research
4/24/2013
More...
|
Addex Therapeutics (ADXN.SW) Receives Approval to Initiate a Phase 1, First-In-Man, Clinical Study for ADX71441
4/24/2013
More...
|
Patrys Limited (PAB.AX) Release: New Data Strengthens PAT-SM6 Profile as an Anti-Cancer Treatment
4/22/2013
More...
|
FDA Approves NeuralStem Inc. to Treat Final Cohort in NSI-189 Phase Ib Trial in Major Depressive Disorder
4/22/2013
More...
|
Senesco Technologies, Inc. (SNT) Announces Completion of Cohort 2 of Its Phase 1b/2a Trial
4/22/2013
More...
|
Karolinska Development AB: Pergamum Announces Last Visit of Last Patient in a Phase I/II Trial of a Potential New Treatment for Hard-to-Heal Wounds
4/19/2013
More...
|
Infectious Disease Research Institute (IDRI) and Medicago, Inc. Report Positive Results for Phase I Clinical Trial for an H5N1 Vaccine
4/18/2013
More...
|
NeuroSigma, Inc. Release: Results of Pediatric Clinical Trial of External Trigeminal Nerve Stimulation for the Treatment of ADHD
4/18/2013
More...
|
Inovio Pharmaceuticals (INO) Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
4/18/2013
More...
|
Collegium Pharmaceutical, Inc. Announces Successful Completion of Clinical Study Evaluating the Impact of Tampering on Oxycodone DETERx®, an Abuse-Deterrent, Extended-Release Opioid Product
4/17/2013
More...
|
BioInvent (BOVNF) Release: Preclinical Data Published in Cancer Cell Highlight Novel Antibody BI-505 and Potent Anti-Myeloma Activity
4/16/2013
More...
|
Advanced Cell Technology Treats First Patient With Better Vision in Clinical Trial for Stargardt's Macular Dystrophy
4/15/2013
More...
|
Genentech (RHHBY)'s Immune Therapy Cancer Drug Shows Promise in Early Study
4/12/2013
More...
|
United Therapeutics Corporation (UTHR) Receives Regulatory Approval to Commence Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension
4/11/2013
More...
|
Patrys Limited (PAB.AX) Completes Treatment of Second Patient Group in Multiple Myeloma Trial
4/10/2013
More...
|
Immunomedics, Inc. (IMMU) Reports First Results of Labetuzumab-SN-38 in Colorectal Cancer
4/9/2013
More...
|
Clinical Trial Sites for First Human Clinical Trial for Treatment of Fatty Liver Disease With Advanced Fibrosis Announced by Galectin Therapeutics
4/9/2013
More...
|
BIND Therapeutics Presents Positive Clinical Data at the American Association for Cancer Research 2013 Annual Meeting for Lead Accurin Candidate, BIND-014, in Cancer Patients
4/9/2013
More...
|
Helix Biopharma (CC:HBP) Initiates Enrollment for Third Cohort and Expansion of Centres in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
4/5/2013
More...
|
Emergent BioSolutions (EBS) to Expand Front Line CLL Clinical Trial of TRU-016 and Rituximab Based on Strong Patient Enrollment and Encouraging Early Clinical Data
4/5/2013
More...
|
Arena Pharmaceuticals, Inc. (ARNA) Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
4/5/2013
More...
|
VG Life Sciences, Inc. (VGLS) Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial
4/4/2013
More...
|
SAGE Therapeutics' Refractory Status Epilepticus Program Demonstrates Efficacy in First-in-Man Experience; Case Study to be Highlighted at International SE Meeting
4/4/2013
More...
|
Aragon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase I Study of ARN-810 in Estrogen Receptor Positive Breast Cancer
4/4/2013
More...
|
Cellular Biomedicine Group Marks the Launch of Clinical Trial for Knee Osteoarthritis (KOA)
4/3/2013
More...
|
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1 Study of ISIS-APOA Rx to Treat Atherosclerosis
4/3/2013
More...
|
Omeros Corporation (OMER) Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
4/2/2013
More...
|
Theraclone Sciences, Inc. Announces Positive Top-Line Data From Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection
4/2/2013
More...
|
Protalix Biotherapeutics, Inc. (PLX) Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease
4/2/2013
More...
|
Pinnacle Biologics Release: Children's Hospital of Wisconsin and Medical College of Wisconsin Launch Clinical Trial for Treatment of Childhood Brain Tumors
4/2/2013
More...
|
Agenix Limited to File for Clinical Trial of Hepatitis B Drug by June
4/1/2013
More...
|
Tengion Inc. Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden
4/1/2013
More...
|
BioMarin Pharmaceutical Inc. (BMRN) Submits CTA for BMN-190 for Batten Disease
4/1/2013
More...
|
Anaeropharma Science Initiates First-in-Human Trial of Novel Recombinant Bifidobacterial Anti-cancer Agent APS001F for Advanced Solid Tumors
3/28/2013
More...
|
Curie-Cancer Trebles Number of Early Phase Clinical Research Studies With Industry Partners
3/26/2013
More...
|
Catabasis Pharmaceuticals, Inc. Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
3/26/2013
More...
|
BIND Biosciences, Inc. Selected for Oral Presentation of BIND-014 Clinical Data at American Association for Cancer Research 2013 Annual Meeting
3/26/2013
More...
|
Omeros Corporation (OMER) Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
3/26/2013
More...
|
Biocryst Pharmaceuticals (BCRX) Announces Initiation of a Phase 1 Clinical Trial of BCX4161 for the Treatment of Hereditary Angioedema
3/25/2013
More...
|
Data From Isis Pharmaceuticals, Inc. (ISIS)-SMN Rx Phase 1 Study in Children With Spinal Muscular Atrophy Presented at the American Academy of Neurology Meeting
3/21/2013
More...
|
Daval International Limited CSO Presents Results From an Exploratory Clinical Trial of AIMSPRO in Amyotrophic Lateral Sclerosis (ALS) at American Academy of Neurology Annual Meeting
3/21/2013
More...
|
MYOS (MYOS) Clinical Research Study Confirms
3/20/2013
More...
|
EGEN, Inc. Announces a Phase I Clinical Trial for Advanced Ovarian Cancer
3/20/2013
More...
|
Upsher-Smith Laboratories Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile of Once-Daily USL255 (Extended-Release Topiramate)
3/20/2013
More...
|
Acorda Therapeutics (ACOR) Release: Diazepam Nasal Spray Demonstrates Comparable Bioavailability to Diazepam Rectal Gel in Pharmacokinetic Study
3/20/2013
More...
|
Upsher-Smith Laboratories Presents Favorable Phase I Data for USL261, a Novel Formulation of Intranasal Midazolam, at 65th Annual Meeting of the American Academy of Neurology
3/19/2013
More...
|
Vince & Associates Clinical Research Sponsors the 14th Annual Phase I & IIa Clinical Trials Conference in London
3/19/2013
More...
|
Trevena, Inc. to Present First-in-Man Study Results for Mu-Opioid Biased Ligand TRV130
3/18/2013
More...
|
Alnylam Pharmaceuticals (ALNY) Initiates Phase I Clinical Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)
3/18/2013
More...
|
Virobay Inc. and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
3/18/2013
More...
|
Anavex Life Sciences Corp. (AVXL.OB) Comments on FDA Plan to Expedite Approval of New Alzheimer's Drugs
3/18/2013
More...
|
Scancell Welcomes New Study in The Journal of Clinical Investigation Suggesting That Melanoma Switches Off the Immune System
3/14/2013
More...
|
Isis Pharmaceuticals, Inc. (ISIS) Reports Clinical Data Showing Blunting of Severe Increases in CRP Following Endotoxin Challenge With ISIS-CRP Rx
3/13/2013
More...
|
Anavex Life Sciences Corp. (AVXL.OB) Release: ANAVEX 2-73 Restores Mitochondrial Functionality, Blocks Cell Death and Oxidative Stress, Preventing Onset of Alzheimer's Disease
3/12/2013
More...
|
Cellceutix (CTIX) Plans for Future Trials Aimed at the Latest Initiatives of "Breakthrough" Designation by the FDA
3/11/2013
More...
|
Bio-Path Holdings, Inc. (BPTH) Begins Enrollment in Fifth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias
3/8/2013
More...
|
Protalex, Inc. (PRTX) to Continue Phase 1b Trial of PRTX-100 in Patients With Active Rheumatoid Arthritis Following Data Safety Monitoring Committee Review
3/7/2013
More...
|
Patrys Limited (PAB.AX) Release: Data From 1st Cohort of Patients in Multiple Myeloma Clinical Trial
3/7/2013
More...
|
Santarus Inc. (SNTS) and VeroScience Announce Publication of American Association of Clinical Endocrinologists Expert Panel Recommendations for CYCLOSET® (bromocriptine mesylate) for the Management of Type 2 Diabetes
3/6/2013
More...
|
Sangamo BioSciences, Inc. (SGMO) Presents New Clinical Data at CROI 2013 Demonstrating Persistent Immune System Improvements After Treatment With ZFN Therapeutic® SB-728-T
3/6/2013
More...
|
Galectin Therapeutics Receives OK From FDA to Proceed Wth First Human Clinical Trial for Treatment of Fatty Liver Disease With Advanced Fibrosis
3/5/2013
More...
|
Relmada Therapeutics Announces LevoCap ER Development Progress
3/5/2013
More...
|
InnaVirVax Announces Presentation of the Results of Its Phase I/IIa Clinical Study at CROI 2013 in Atlanta
3/5/2013
More...
|
NeuroDerm Ltd. Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinson's Disease
3/4/2013
More...
|
Shape Pharmaceuticals Provides Update on SHP-141 Topical HDAC Inhibitor Clinical Development for Cutaneous T Cell Lymphoma
3/4/2013
More...
|
Targeted Medical Pharma Reports New Data on Red Blood Cell Stimulating Formulation
3/4/2013
More...
|
Polyphor Reports Successful Phase I Results for Its Pseudomonas Selective Antibiotic POL7080
3/4/2013
More...
|
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Hail Results of Dermatitis Study
3/4/2013
More...
|
PROMETHERA Biosciences S.A./N.V. Opens the French Part of Its Clinical Trial in Cell Therapy
2/28/2013
More...
|
Oraya Therapy™ Continues to Show Efficacy for Wet Age-Related Macular Degeneration
2/28/2013
More...
|
Integrated BioTherapeutics Release: New Bioterrorism Vaccine Gets First Test In Humans
2/27/2013
More...
|
Arrowhead Research Corporation (ARWR) Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B Virus
2/26/2013
More...
|
United Therapeutics Corporation (UTHR) Moves Forward Towards a Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension
2/26/2013
More...
|
Cellceutix (CTIX) Reports on Kevetrin Clinical Trials and Prurisol Manufacturing
2/25/2013
More...
|
Quinten Identifies a Combination of Two Synergistic Markers That Predicts a Favorable Response to Treatment in Triple-Negative Breast Cancer
2/25/2013
More...
|
Avaxia Biologics, Inc. Announces First Patient Dosed in Phase 1b Study of AVX-470 in Ulcerative Colitis
2/25/2013
More...
|
SFDA Grants Approval to Sihuan Pharmaceutical Holdings Group Ltd. for Clinical Trial of Innovative Drug -- Pinoxacin Hydrochloride
2/22/2013
More...
|
Pluristem Therapeutics (PSTI) Obtains Orphan Drug Status for Aplastic Anemia Treatment
2/21/2013
More...
|
Fibrocell Science, Inc. Initiates New Study on Autologous Creme
2/20/2013
More...
|
Advaxis, Inc. Announces Phase 1/2 Trial of ADXS-HPV in Anal Cancer Conducted by Brown University Oncology Group
2/19/2013
More...
|
Intra-Cellular Therapies, Inc. Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
2/19/2013
More...
|
Gamida Cell Ltd.'s NiCord® Demonstrates Successful Engraftment in Patients With Hematological Malignancies in Phase I/II Study
2/15/2013
More...
|
Clasado Announces Positive Results of Clinical Study of Bimuno® for Metabolic Syndrome
2/15/2013
More...
|
Lentigen Corporation Receives U.S. Orphan Drug Designation for Novel Gene Therapy for Glioblastoma Multiforme
2/14/2013
More...
|
Verastem, Inc. (VSTM) Files for Orphan Disease Status for VS-6063 in Mesothelioma
2/14/2013
More...
|
Dompe Release: The First Patient Has Been Enrolled in the First International Clinical Trial of rhNGF for the Treatment of Neurotrophic Keratitis
2/14/2013
More...
|
Progenics Pharmaceuticals, Inc. (PGNX) Presents Updated Data From Phase 1 Study of PSMA ADC
2/14/2013
More...
|
Positive Data From Celldex Therapeutics, Inc. (CLDX)'s Phase 1 Study of CDX-301 Support Initiation of Pilot Study in Hematopoietic Stem Cell Transplantation
2/14/2013
More...
|
Catabasis Pharmaceuticals, Inc. Announces Positive Phase 1 Data for CAT-1004 Validating the SMART Linker Technology Platform
2/11/2013
More...
|
Advanced Cell Technology's Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using the Company's hESC-derived Cells to Treat Severe Myopia
2/11/2013
More...
|
Apogenix Receives FDA Orphan Drug Designation for Apocept™ to Treat Myelodysplastic Syndromes and Initiates Clinical Phase I Study
2/7/2013
More...
|
VAXIMM Study Meets Endpoints in Phase 1/2
2/7/2013
More...
|
Verastem, Inc. (VSTM) Release: Scientific Data on PI3K/mTOR Inhibitor VS-5584 Published in Molecular Cancer Therapeutics
2/6/2013
More...
|
Seattle Genetics, Inc. (SGEN) Initiates Two Phase I Trials of SGN-CD19A
2/6/2013
More...
|
First Patient Treated in Genelux Corporation Phase I Trial With GL-ONC1 at Memorial Sloan-Kettering Cancer Center
2/6/2013
More...
|
Synageva BioPharma (GEVA) Release: Hepatology Publishes 12-Week Phase I/II Extension Study Data of Sebelipase Alfa in Adults With Late Onset LAL Deficiency
2/5/2013
More...
|
Verastem, Inc. (VSTM) Initiates Phase 1/1b Clinical Trial of VS-6063 Plus Paclitaxel for Patients With Ovarian Cancer
2/5/2013
More...
|
Genethon Receives Approval From the UK Medicine Regulatory Agency to Start a New Clinical Trial for an Inherited Immune Deficiency: Chronic Granulomatous Disease
2/5/2013
More...
|
Cytos Biotechnology AG VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
2/4/2013
More...
|
Tengion Inc. Announces Clinical Progress for Neo-Urinary Conduit™ Phase 1 Trial and Regulatory Advance for Neo-Kidney Augment™
1/31/2013
More...
|
Arteriocyte, Inc. Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
1/31/2013
More...
|
VG Life Sciences, Inc. (VGLS) Reports Positive Results from First Stage of Ovarian Cancer Clinical Trial Using Sorafenib (Nexavar) Combined With Hydroxychloroquine
1/31/2013
More...
|
OncoEthix Doses First Patient in Its Phase I Trial of OTX015, a BET Bromodomain Inhibitor for the Treatment of Hematologic Malignancies
1/31/2013
More...
|
PaxVax, Inc. Announces Positive Results for Oral Ad4 Vaccine Technology
1/31/2013
More...
|
RXi Pharmaceuticals (RXII) Announces Completion of Enrollment in Second Phase 1 Trial for RXI-109 Program
1/30/2013
More...
|
Alnylam Pharmaceuticals (ALNY) and Collaborators Publish Results from Phase I Clinical Trial and Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer
1/30/2013
More...
|
Medgenics, Inc. Launches First Clinical Trial in Hepatitis to Use INFRADURE Tissue Treatment
1/30/2013
More...
|
OncoPep Initiates Phase 1/2a Clinical Trial with Multi-Peptide Vaccine to Treat Smoldering Multiple Myeloma
1/29/2013
More...
|
FDA Grants Soligenix (SNGX.OB) Fast Track Designation for OrbeShield(™) for the Reduction of Mortality Associated With Gastrointestinal Acute Radiation Syndrome (GI ARS)
1/29/2013
More...
|
La Jolla Pharmaceutical Company (LJPC) Announces First Patient Treated in Clinical Trial of GCS-100 in Chronic Kidney Disease
1/28/2013
More...
|
Boston Therapeutics, Inc. Announces Clinical Study Final Results Indicate That SUGARDOWN® Reduced the Post-Meal Elevation of Blood Glucose by Up to 61% in Healthy Volunteers
1/28/2013
More...
|
Algeta Initiates New Oncology Research Program to Evaluate the Potential of a Targeted Thorium Conjugate (TTC) Based on Immunomedics, Inc. (IMMU)'s Anti-CD22 Monoclonal Antibody
1/28/2013
More...
|
Synergy Pharmaceuticals Initiates Multiple Ascending Dose Phase Ib Trial in Healthy Volunteers of SP-333, a Second Generation Guanylate Cyclase C Agonist for the Treatment of Ulcerative Colitis
1/28/2013
More...
|
Oncolytics Biotech Inc. (ONC.TO) Announces Positive REOLSYIN® Clinical Trial Data Presented at ASCO Gastrointestinal Cancers Symposium
1/28/2013
More...
|
Seattle Genetics, Inc. (SGEN) Announces Data from ASG-5ME Phase I Clinical Trial for Pancreatic Cancer
1/25/2013
More...
|
BioInvent (BOVNF): Positive Results From the BI-505 Phase I Study in Multiple Myeloma
1/24/2013
More...
|
Curis, Inc. (CRIS) Announces Dosing of First Patient in Phase I Clinical Trial of Dual PI3 Kinase and HDAC Inhibitor CUDC-907
1/24/2013
More...
|
VistaGen Therapeutics, Inc. Successfully Completes Final Phase 1 Safety Study of AV-101
1/23/2013
More...
|
Trevena, Inc. GPCR Platform Yields a Novel Mu-opioid Biased Ligand Analgesic With Side Effect Benefits
1/23/2013
More...
|
Omeros Corporation (OMER) Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
1/22/2013
More...
|
Patients With Better Vision to be Enrolled in Advanced Cell Technology’s Clinical Trials for Macular Degeneration
1/22/2013
More...
|
Details of HER-2/Neu Class I Antigen Licensed by TapImmune Inc. (TPIV) Published in Journal of Immunology: Antigen is a Naturally Processed Epitope for Breast Cancer Vaccines
1/22/2013
More...
|
Karyopharm Therapeutics Initiates Treatment of Patients With Acute Myeloid Leukemia (AML) in Phase 1 Trial With Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE)
1/17/2013
More...
|
Astex Pharmaceuticals (ASTX) Release: Cancer Research Technology and Cancer Research UK Cambridge Research Institute Initiate AT13148 Clinical Trial to Treat Several Cancer Types
1/17/2013
More...
|
Molecular Partners AG Announces Publication of Results From a Phase I/II Clinical Trial of Its anti-VEGF DARPin MP0112 in Diabetic Macular Edema
1/17/2013
More...
|
Patrys Limited (PAB.AX) Progresses Multiple Myeloma Clinical Trial to Second Patient Group
1/15/2013
More...
|
VG Life Sciences, Inc. (VGLS) Expands Ovarian Cancer Trial; Approved to Study Treatment of Breast, Colon, Lung, Liver and Pancreas Cancer
1/15/2013
More...
|
Soterix Medical Announces Completion of Stroke-Aphasia Trial
1/15/2013
More...
|
NeuralStem Inc. Receives FDA Approval to Commence Spinal Cord Injury Trial
1/14/2013
More...
|
GeoVax Labs Inc. (GOVX.OB) Announces Enrollment Completion for Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
1/10/2013
More...
|
BioTime (BTX) Submits Protocol for Initiation of Human Clinical Trials of Renevia™ in Europe
1/10/2013
More...
|
Proteo, Inc. / Proteo Biotech AG: FDA Grants Proteo Orphan Drug Designation to Elafin for the Treatment of Pulmonary Arterial Hypertension
1/10/2013
More...
|
TapImmune Inc. (TPIV) Release: Positive Interim Safety Analysis Achieved in Breast Cancer Patients Treated With HER2/neu Antigens
1/9/2013
More...
|
TG Therapeutics, Inc. (MHA) Initiates First-In-Human, Phase I Clinical Trial for Its Novel, Highly Specific PI3K-Delta Inhibitor, TGR-1202, in Patients With Hematologic Malignancies
1/8/2013
More...
|
Advanced Cell Technology Achieves Clinical Milestone
1/8/2013
More...
|
Provectus Pharmaceuticals Inc. Announces H. Lee Moffitt Cancer Center & Research Institute Initiates Phase 1 Study of PV-10 to Elucidate Bystander Effect
1/8/2013
More...
|
Spectrum Pharmaceuticals, Inc. (SPPI) Announces Positive RenaZorb® Phase 1 Clinical Data Demonstrating Robust Activity in Easy-to-Swallow Pill Formulation
1/7/2013
More...
|
EPIRUS Biopharmaceuticals, Inc. Announces Positive Phase 1 Data for BOW-015
1/7/2013
More...
|
ChemoCentryx, Inc. (CCXI) Advances a New Generation CCR9 Inhibitor, CCX507, Into Clinical Development
1/7/2013
More...
|
Baxter International, Inc. (BAX) to Initiate Late-Stage Clinical Trial of BAX 855 for the Treatment of Hemophilia A
1/7/2013
More...
|
Kinex Pharmaceuticals and Hanmi Pharmaceutical, Co., Ltd Announce First Patient has been Enrolled in Phase 1b/IIa Clinical Trial in Korea
1/7/2013
More...
|
Vaccinex, Inc. Announces Initiation of a Phase 1 Clinical Trial of VX15/2503 Antibody in Multiple Sclerosis Patients
1/7/2013
More...
|